Regulatory FDA turns to old drugs to address new diseases, persistent medical needs BioSpaceThe FDA is looking to retool drugs with sufficient evidence to support their use in other indications, particularly those with unmet need.Read full story pharminent May 12, 2026 (Last updated: May 16, 2026) BioSpace The FDA is looking to retool drugs with sufficient evidence to support their use in other indications, particularly those with unmet need. Read full story Post navigation Previous: Novo says high-dose Wegovy can cause 28% weight lossNext: BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026